We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 17, 2022

Abiraterone Acetate and Prednisolone ± Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

The Lancet


Additional Info

The Lancet
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Lancet 2021 Dec 23;[EPub Ahead of Print], G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, S Gillessen, A Cook, C Brawley, CL Amos, N Atako, C Pugh, M Buckner, S Chowdhury, Z Malik, JM Russell, C Gilson, H Rush, J Bowen, A Lydon, I Pedley, JM O'Sullivan, A Birtle, J Gale, N Srihari, C Thomas, J Tanguay, J Wagstaff, P Das, E Gray, M Alzoueb, O Parikh, A Robinson, I Syndikus, J Wylie, A Zarkar, G Thalmann, JS de Bono, DP Dearnaley, MD Mason, D Gilbert, RE Langley, R Millman, D Matheson, MR Sydes, LC Brown, MKB Parmar, ND James

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading